[An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]

Hua Xi Yi Ke Da Xue Xue Bao. 2001 Dec;32(4):599-601.
[Article in Chinese]

Abstract

Objective: To investigate the effect of IL-2, IFN and bcr-abl AS-ODN on bone marrow purging in vitro for patients with chronic myelogenous leukemia (CML).

Methods: By amplifying in vitro clone forming culture, and purging the bone marrow of 5 CML patients through different combined use of IL-2, IFN and bcr-abl AS-ODN, we compared the effects of 4 combined regimens.

Results: It was found that the suppressive effects of the 4th regimen combining IL-2 (800 U/ml), IFN (800 u/ml) and bcr-abl AS-ODN (30 micrograms/ml) on leukemia cell clone forming unit (CFU) were significantly different from the suppressive effects of the other 3 regimens (P < 0.01). With the use of the 4th regimen, the GM-CFU and L-CFU survival rates were 26.91% and 3.49% respectively (P < 0.01).

Conclusion: The combined regimen of IL-2 (800 U/ml), IFN (800 u/ml) and bcr-abl AS-ODN (30 micrograms/ml) has good effect on selective CML bone marrow purging in vitro and can be used in clinical purging of CML bone marrow.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow Cells / cytology
  • Bone Marrow Purging*
  • Bone Marrow Transplantation*
  • Cell Separation
  • Cells, Cultured
  • Fusion Proteins, bcr-abl / pharmacology
  • Humans
  • Interferon-alpha / pharmacology
  • Interleukin-2 / pharmacology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Leukocytes, Mononuclear / cytology
  • Oligonucleotides, Antisense / pharmacology

Substances

  • Interferon-alpha
  • Interleukin-2
  • Oligonucleotides, Antisense
  • Fusion Proteins, bcr-abl